Skip to main content
Fig. 7 | Journal of Patient-Reported Outcomes

Fig. 7

From: Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study

Fig. 7

Probability of patients reporting ≥ 28-point improvement from baseline in SNOT-22 total score over time. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. OR (mepolizumab vs placebo) of percentage of patients reporting ≥ 28 point improvement from baseline in SNOT-22 total score. OR > 1 indicates greater efficacy of mepolizumab. CI Confidence interval, OR Odds ratio, SC subcutaneous, SNOT-22 Sino-nasal outcome test-22

Back to article page